AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36528522
Drug: BI 1810631
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1810631 (15 mg BID, escalating doses)
Trial: 36528522
Drug: BI 1810631
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1810631 (escalating doses)
Trial: 36528793
Drug: AZD8601 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8601 (3 mg total, 30 epicardial injections)
Trial: 36529052
Drug: CoronaVac (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (first dose on D0, second dose on D28, booster dose on D210)
Trial: 36529052
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of CoronaVac (D240)
Trial: 36529089
Drug: Extended-release calcifediol
RxNorm normalized name: calcifediol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release calcifediol (ERC) 300 mcg on days 1-3 and 60 mcg on days 4-27
Trial: 36529145
Drug: Overall treatment-related
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment-related serious adverse events
Trial: 36529145
Drug: Treatment-emergent deaths
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent deaths during induction
Trial: 36529145
Drug: Treatment-emergent deaths
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent deaths during maintenance after HSCT
Trial: 36529152
Drug: Sequential transarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential transarterial chemoembolisation (TACE) followed by stereotactic body radiotherapy (27·5-40·0 Gy in five fractions) and avelumab (10 mg/kg) administered 14 days after radiotherapy and every 2 weeks thereafter.
Trial: 36529613
Drug: Single-agent regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-agent regorafenib (RegI)
Trial: 36529709
Drug: IV lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV lacosamide infusion (2-12 mg/kg/day or 100-600 mg/day; 15-60 minutes infusion)
Trial: 36529709
Drug: IV lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV lacosamide infusion
Trial: 36529811
Drug: Dupilumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab plus topical corticosteroids (200 mg for 5 kg to < 15 kg; 300 mg for 15 kg to < 30 kg) every 4 weeks for 16 weeks
Trial: 36529949
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin
Trial: 36530003
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with dignity
Trial: 36531070
Drug: Nano-Pulse Stimulation™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-Pulse Stimulation™ (NPS™) therapy
Trial: 36531460
Drug: Lactobacilli-loaded vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacilli-loaded vaginal capsules (one capsule per day for 10 days)
Trial: 36531460
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one capsule per day for 10 days)
Trial: 36531900
Drug: Maintenance tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maintenance tobramycin inhalation solution (TIS) once daily
Trial: 36532014
Drug: CD19-directed Piggy
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-directed Piggy Bac CAR T cell therapy (pbCAR-T)
Trial: 36532031
Drug: ChAd63 MVA
RxNorm normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd63 MVA ME-TRAP vaccine
Trial: 36532058
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of subcutaneous atacicept
Trial: 36532058
Drug: Weekly administrations
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administrations of atacicept for one year
Trial: 36532058
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of atacicept
Trial: 36532545
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g eicosapentaenoic acid (EPA) + 1.2 g docosahexaenoic acid (DHA)/day for 6 months
Trial: 36532582
Drug: Dermal vacuum
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal vacuum massage therapy (as an adjunct to the main intervention).
Trial: 36533429
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (cisplatin + 5-fluorouracil or capecitabine)
Trial: 36533622
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment plus endovascular treatment (EVT)
Trial: 36533798
Drug: DaxibotulinumtoxinA-lanm for
RxNorm normalized name: daxibotulinumtoxinA-lanm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DaxibotulinumtoxinA-lanm for injection (DAXI) 40U (glabellar), 32U (forehead), 48U (lateral canthal)
Trial: 36533948
Drug: Adjuvanted, inactivated
RxNorm normalized name: Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted, inactivated vaccines
Trial: 36533948
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza virus vaccine
Trial: 36533948
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza virus vaccines without adjuvant
Trial: 36534208
Drug: Tofacitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib monotherapy
Trial: 36534274
Drug: Ofatumumab 20
RxNorm normalized name: ofatumumab 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab 20 mg subcutaneously
Trial: 37265222
Drug: Semaglutide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide treatment
Trial: 36534474
Drug: Immediate initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate initiation of antibiotics after culture
Trial: 36534474
Drug: Specimen-initiated antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specimen-initiated antibiotic protocol
Trial: 36534717
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg administered after delivery
Trial: 36534825
Drug: IFX s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFX s.c. 120 mg every 2 weeks
Trial: 36534825
Drug: IFX i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFX i.v. 3 mg/kg every 8 weeks
Trial: 36534942
Drug: Crizotinib (CZ)
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib (CZ) with chemotherapy
Trial: 36534976
Drug: DART (Decision-Aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DART (Decision-Aid for Renal Therapy)
Trial: 37149056
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus olanzapine
Trial: 36535196
Drug: Chemoradiotherapy (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (50 Gy, 2 Gy/f, 5 weeks with capecitabine: 800 mg/m2)
Trial: 36535300
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg daily
Trial: 36535524
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 or 300 mg every 2 weeks up to 52 weeks
Trial: 36535765
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity (PA) intervention with individualized exercise prescription and mHealth device providing heart rate-based just-in-time (JIT) feedback on PA intensity.
Trial: 36535765
Drug: Healthy aging
RxNorm normalized name: CVS Healthy Aging Probiotic Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy aging education condition with a reading prescription and weekly quizzes.
Trial: 36535779
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with Aspirin
Trial: 36536016
Drug: Comprehensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive intervention package including monthly food vouchers for eggs, milk, semolina, sugar, and oil, multiple micronutrient powder (MNP), counseling on child feeding and handwashing.
Trial: 36536114
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (0.25 g/kg fat free mass)
Trial: 36536114
Drug: Cricket protein
RxNorm normalized name: cricket allergenic extract
DrugBank: Acheta domesticus (DB10866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cricket protein (0.25 g/kg fat free mass)
Trial: 36536114
Drug: Pea protein
RxNorm normalized name: Pea Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pea protein (0.25 g/kg fat free mass)
Trial: 36536364
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 2 g per day for 8 weeks
Trial: 36536916
Drug: Psilocybin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (single dose)
Trial: 36537346
Drug: ABBV-47D11 (180,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-47D11 (180, 600, or 2400 mg)
Trial: 36537346
Drug: ABBV-47D11 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-47D11 (600 mg or higher)
Trial: 36537346
Drug: ABBV-47D11 (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-47D11 (any dose)
Trial: 36537742
Drug: KN015 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN015 (20 μg)
Trial: 36537742
Drug: KN015 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN015 (40 μg)
Trial: 36537742
Drug: KN015 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN015 (60 μg)
Trial: 36537785
Drug: Psyllium (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (7.5 g per day)
Trial: 36538098
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment (no specific treatment for hypersalivation)
Trial: 36538166
Drug: Passive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive therapy (n=14)
Trial: 36538189
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + High-Intensity Laser Therapy (HILT)
Trial: 36538259
Drug: Mitazalimab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitazalimab (600 μg/kg)
Trial: 36538259
Drug: Mitazalimab (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitazalimab (2000 μg/kg)
Trial: 36538309
Drug: ICE care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE care model (risk-stratified, multidisciplinary intervention combining physical therapy, health coach counseling, and specialist consultation)
Trial: 36538309
Drug: Individualized postural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized postural therapy (IPT, combining physical therapy with self-efficacy and self-management)
Trial: 36538328
Drug: 12 weekly,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weekly, 30-minute virtual health coach sessions + 11 weekly cooking videos and associated home-delivered groceries
Trial: 36538409
Drug: ExPlas (exercise-trained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ExPlas (exercise-trained plasma) transfusion from young, healthy, fit adults, administered once a month for 4 months.
Trial: 36538782
Drug: Soticlestat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat (100 mg twice daily, titrated up to 300 mg twice daily)
Trial: 36539568
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula therapy
Trial: 36539711
Drug: 15 mg/hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/hour intravenous clazosentan
Trial: 36539734
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) group
Trial: 36539736
Drug: Chlorhexidine mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthrinse (0.12% chlorhexidine gluconate, gargled for 1 minute with 100 mL)
Trial: 36539810
Drug: 40-mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mg dose of doxycycline
Trial: 36539810
Drug: 200-mg antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg antibiotic dose of doxycycline
Trial: 36540016
Drug: Aspiration during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration during intramuscular injection
Trial: 36540016
Drug: No aspiration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspiration during intramuscular injection
Trial: 36541390
Drug: Heart-shaped intrauterine
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart-shaped intrauterine balloon inserted immediately after hysteroscopic adhesiolysis, left in place for 7 days under antibiotic prophylaxis.
Trial: 36542081
Drug: CF1 (340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF1 (340 µg dexamethasone)
Trial: 36542081
Drug: CF2 (340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF2 (340 µg dexamethasone)
Trial: 36542086
Drug: avalglucosidase alfa
RxNorm normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: avalglucosidase alfa 20 mg/kg every other week for 6 months
Trial: 36542086
Drug: avalglucosidase alfa
RxNorm normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: avalglucosidase alfa 40 mg/kg every other week for 6 months
Trial: 36542086
Drug: alglucosidase alfa
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: alglucosidase alfa (current stable dose) for 6 months
Trial: 36542261
Drug: Continuous terlipressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous terlipressin infusion (CONI), 4 mg/24 h for 5 days
Trial: 36542261
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus terlipressin (BOL), 2 mg every 4 h
Trial: 36542261
Drug: Continuous terlipressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous terlipressin infusion (CONI)
Trial: 36542261
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus terlipressin (BOL)
Trial: 36542308
Drug: PVO-OS (0.025,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVO-OS (0.025, 0.05, or 0.10 mg/mL)
Trial: 36542382
Drug: Thrice-weekly structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly structured exercise
Trial: 36542382
Drug: Once-weekly structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly structured exercise
Trial: 36542826
Drug: Lisocabtagene maraleucel
RxNorm normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisocabtagene maraleucel (liso-cel) - 100 × 10^6 chimeric antigen receptor-positive T cells
Trial: 36542826
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) - 3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders
Trial: 36543503
Drug: 7-day ECG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day ECG patch screening
Trial: 37040116
Drug: Lecanemab 10
RxNorm normalized name: LECANEMAB 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [LEQEMBI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab 10 mg/kg biweekly
Trial: 36544211
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of soybeans and flaxseeds (~ 200 mg of phytoestrogens) until surgery (approximately 6 weeks)
Trial: 36545256
Drug: Thiopurine 6-thioguanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopurine 6-thioguanine (6TG) treatment
Trial: 36545312
Drug: Ticagrelor treatment
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor treatment in patients with CYP3A4*22 and CYP3A5 genotypes
Trial: 36546479
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (4 μg/kg initial dose, followed by 2 μg/kg if needed)
Trial: 37660704
Drug: Weekly dupilumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly dupilumab (300 mg)
Trial: 37660704
Drug: Dupilumab every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab every 2 weeks (300 mg)
Trial: 36546626
Drug: Lentiviral gene-corrected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentiviral gene-corrected autologous CD34+ cells infusion
Trial: 36546659
Drug: Adagrasib monotherapy
RxNorm normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adagrasib monotherapy (600 mg orally twice daily)
Trial: 36546659
Drug: Adagrasib in
RxNorm normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adagrasib in combination with cetuximab (initial loading dose of 400 mg/m², followed by 250 mg/m² weekly or 500 mg/m² every 2 weeks)
Trial: 36547147
Drug: Linac-based SBRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linac-based SBRT on the prostate bed, total dose of 32.5 Gy in five fractions every other day.
Trial: 36547262
Drug: Posterior quadratus
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior quadratus lumborum block (QLB) with 3.75 mg/ml ropivacaine 20 ml/side
Trial: 36547975
Drug: Oral β-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral β-glucan during the first 5 weeks of vaccine priming (group 2)
Trial: 36547975
Drug: GD2/GD3 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GD2/GD3 vaccine without β-glucan (group 1)
Trial: 36547975
Drug: Oral β-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral β-glucan during vaccine boost (both groups)
Trial: 36547975
Drug: Anti-GD2 IgG1
RxNorm normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-GD2 IgG1 titer of 230 ng/mL or greater by week 8
Trial: 36547975
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of antibody titer with dectin-1 SNP
Trial: 36547975
Drug: Vaccine-related toxic
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-related toxic effects
Trial: 36548225
Drug: 7-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of any active antibiotic
Trial: 36548225
Drug: 14-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of any active antibiotic
Trial: 36548338
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care Exercise Prescription (UCEP)
Trial: 36548444
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (single dose of praziquantel)
Trial: 36548444
Drug: Intense treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense treatment (4 repeated doses of praziquantel at 2-week intervals)
Trial: 36549308
Drug: Tenecteplase (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (0.25 mg per kg of bodyweight, maximum 25 mg)
Trial: 36549320
Drug: Levofloxacin-based sequential
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-based sequential quadruple therapy for 14 days (EAML14); esomeprazole 40 mg and amoxicillin 1 g for 7 days, followed by esomeprazole 40 mg, metronidazole 500 mg, and levofloxacin 250 mg for 7 days, all twice-daily.
Trial: 36549320
Drug: Bismuth-based quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based quadruple therapy for 10 days (BQ10); esomeprazole 40 mg twice daily, bismuth tripotassium dicitrate 300 mg four times a day, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day.
Trial: 36549320
Drug: Levofloxacin-based sequential
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-based sequential quadruple therapy (EAML14) and Bismuth-based quadruple therapy (BQ10)
Trial: 36549723
Drug: Pharmacist-conducted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-conducted medication reconciliation